Seeking Alpha

Mylan Inc (MYL)

  • Wed, Oct. 14, 1:09 PM
    • Mylan (MYL +1.4%) executives did their best to sell the merits of the company's hostile bid for Perrigo (PRGO +1.2%) but some analysts were not inspired.
    • RBC's Randall Stanicky thinks Mylan's rationale "falls short on several points." In particular, he cites Mylan's assertion that Perrigo's "unaffected" stock price is ~$129 (currently exchanging hands at $160) implying a 13x P/E (2017).
    • Jeffries' David Steinberg states that "although some of Mylan's arguments were thoughtfully presented...most failed to resonate...we continue to see lackluster financial/strategic benefits for Perrigo and Mylan's presentation ultimately failed to convince us that tendering would be the right move for fundamentally focused PRGO investors." Adding, "...we believe Mylan's analysis conspicuously overlooks the meager share price premium being offered - particularly since we're not sure we agree with Mylan's calculation of Perrigo's "unaffected" share price."
    • Leerink's Jason Gerberry cites "several deal uncertainties that were not addressed" in the presentation, specifically how Mylan expects to achieve the cost synergy target of $800M and whether Mylan has the support of 80% of Perrigo shareholders considering that merger arbs own as much as 25% of PRGO per recent 13-F filings. He also cites the disagreement between the companies regarding Irish takeover law and the inability of his group to find any statutory provisions that support Mylan's view on the issue.
    • Mylan's most recent bid for Perrigo was $75 per share in cash plus 2.3 shares of MYL for each PRGO share. Based on a recent price for MYL, the value of the offer is $171.60, representing a premium of only 7% for PRGO shareholders.
    | Wed, Oct. 14, 1:09 PM | Comment!
  • Tue, Oct. 13, 4:39 PM
    • Mylan (NASDAQ:MYL) is slipping on its salesperson shoes today at 5:00 pm ET for a webcast and conference call to review the positives of a marriage with Perrigo (NYSE:PRGO). Chairman Robert Coury, CEO Heather Bresch and CFO John Sheehan will host.
    | Tue, Oct. 13, 4:39 PM | 2 Comments
  • Tue, Oct. 13, 3:49 PM
    • Getting out in front of what should be more bashing of their business models at the Democratic debate tonight, the healthcare names (XLV -1.3%) have about doubled the decline in the S&P 500. Within healthcare, it's the biotechs (IBB -3.1%) and pharmaceuticals (XPH -3.2%) leading the way south.
    • Celgene (CELG -3.3%), Biogen (BIIB -3.6%), Amgen (AMGN -3.5%), Allergan (AGN -4.1%), Mylan (MYL -3.6%)
    • The biotech heavy Russell 2000 (IWM -1.4%) is feeling the pain as well.
    | Tue, Oct. 13, 3:49 PM | 27 Comments
  • Fri, Sep. 25, 3:07 PM
    | Fri, Sep. 25, 3:07 PM | 134 Comments
  • Thu, Sep. 24, 3:50 PM
    • The U.S. Court of Appeals of the Federal Circuit upholds the ruling by the U.S. District Court for the District of New Jersey that 18 claims from four Shire (SHPG +0.5%) patents covering Vyvanse (lisdexamfetamine dimesylate) are valid. The patent claims cover the lisdexamfetamine dimesylate compound and a method of using the compound for the treatment of attention deficit hyperactivity disorder (ADHD).
    • The ruling means that Shire's patents will be valid until 2023 which is, obviously, bad news to the five would-be generic competitors who filed Abbreviated New Drug Applications (ANDAs): Actavis (AGN +1.4%), Amneal Pharmaceuticals, Mylan (MYL +0.7%), Roxane Laboratories and Sandoz (NVS -0.6%).
    | Thu, Sep. 24, 3:50 PM | 1 Comment
  • Tue, Sep. 22, 7:06 PM
    • Drugmaker Mylan (MYL -3.1%) -- in the middle of a contentious hostile pursuit of Perrigo (PRGO -1.6%) -- has countersued Perrigo over "serious misstatements" it's made about the $27B tender.
    • Those statements were in the lawsuit that Perrigo filed last Thursday, which sought to block any tender offer unless Mylan corrected its misleading statements about the merger.
    • Since an April 8 bid, Perrigo stock is down 10.3%; Mylan is down 29.6% over the same period. Shares of both companies are flat in after-hours action.
    | Tue, Sep. 22, 7:06 PM | 5 Comments
  • Fri, Sep. 18, 7:44 AM
    • Mylan (NASDAQ:MYL) launches Fluvastin Sodium Extended-release Tablets, 80 mg, in the U.S. for the treatment of patients with hypercholesterolemia and mixed dyslipidemia. The product is the generic equivalent of Novartis' Lescol XL Tablets.
    • Per IMS Health, Lescol generated almost $38M in U.S. sales in the 12-month period ending June 30.
    | Fri, Sep. 18, 7:44 AM | Comment!
  • Thu, Sep. 17, 7:05 AM
    • As expected, Perrigo's (NYSE:PRGO) Board of Directors unanimously determines that Mylan's (NASDAQ:MYL) $27.1B bid for the company is inadequate and substantially undervalues the company. In a letter to shareholders, President, CEO & Chairman Joseph Papa urges them not to tender shares.
    • Perrigo will host a conference call this morning at 8:00 am ET to discuss the situation.
    | Thu, Sep. 17, 7:05 AM | Comment!
  • Tue, Sep. 8, 11:49 AM
    • Mylan N.V. (MYL +0.5%) intends to start its $27.1B hostile takeover of Perrigo (PRGO +1.3%) on Monday, September 14 when it will ask the latter's shareholders to accept the proposal that management rejected.
    • Mylan's offer is $75 in cash plus 2.3 MYL shares for each PRGO share, which values the deal at $185.52 per share or a 2.6% premium to this morning's price of $180.90.
    • Mylan Chairman Robert Coury says, "We are confident that Perrigo shareholders see that our offer provides superior immediate value as well as long-term, sustainable value creation."
    | Tue, Sep. 8, 11:49 AM | 11 Comments
  • Fri, Aug. 28, 8:36 AM
    • Perrigo (NYSE:PRGO) is confident its shareholders will reject Mylan's (NASDAQ:MYL) planned unsolicited offer to acquire the company.
    • "We are confident that most of them [shareholders] believe that Mylan's offer substantially undervalues Perrigo and would dilute our growth profile and superior valuation," Perrigo CEO Joseph Papa said.
    • Mylan intends to launch a formal offer to Perrigo shareholders in the coming weeks.
    • Previously: Mylan shareholders support acquisition of Perrigo (Aug. 28 2015)
    | Fri, Aug. 28, 8:36 AM | 12 Comments
  • Fri, Aug. 28, 8:03 AM
    • Mylan (NASDAQ:MYL) shareholders have overwhelmingly approved the proposed acquisition of Perrigo (NYSE:PRGO) and the related issuance of common stock to the latter's shareholders.
    • Mylan now intends to launch a formal offer to Perrigo shareholders in the coming weeks.
    • Previously: Mylan's vote on Perrigo approaches (Aug. 28 2015)
    | Fri, Aug. 28, 8:03 AM | 2 Comments
  • Fri, Aug. 28, 2:47 AM
    • Mylan (NASDAQ:MYL) shareholders are scheduled to vote today on a matter related to its $36B hostile takeover bid for pharmaceutical company Perrigo (NYSE:PRGO).
    • The vote - on whether Mylan can issue new stock for the offer - will be a critical step in moving forward with that bid.
    • Although proxy advisory firm ISS has recommended that investors vote no, two of Mylan's biggest shareholders have already publicly supported the deal.
    | Fri, Aug. 28, 2:47 AM | Comment!
  • Tue, Aug. 25, 3:57 PM
    • Generic drugmaker Mylan's (NASDAQ:MYL) $35.1B hostile offer for Perrigo (NYSE:PRGO) is staying fairly hostile, as Perrigo chief Joseph Papa wrote shareholders today charging Mylan with threatening to delist Dublin-based Perrigo, from “every stock exchange, even if 49 percent of our holders say no to its offer."
    • He's still highly negative about Mylan's change to acceptance conditions for the deal, to a 50% threshold from the previous 80%.
    • Parts of Papa's statement may have misled shareholders or the market, in violation of rules, the Irish Takeover Panel says. Mylan responded with a statement calling Perrigo's comments "misleading."
    • Separately, Mylan has launched a generic form of Pfizer's anti-infection injection Zosyn in the U.S., and noted that the Patent and Trademark Office has opened a review of the validity of two Copaxone patents licensed to Teva. Mylan sees its generic version of the multiple sclerosis treatment as "an exciting first-to-file opportunity."
    • Previously: Shareholder vote advisor recommends Mylan investors nix Perrigo deal (Aug. 14 2015)
    • Previously: Perrigo less than thrilled with Mylan's threshold-lowering maneuver (Aug. 13 2015)
    | Tue, Aug. 25, 3:57 PM | 8 Comments
  • Tue, Aug. 18, 1:40 PM
    • In response to receiving a warning letter from the FDA on August 6 related to quality deficiencies observed during inspections in 2014 and early 2015 at three manufacturing sites in India, Mylan (MYL +0.3%) CEO Heather Bresch says the agency's action will have no material impact on the company's business or financial guidance.
    • A warning letter is a list of deficiencies requiring the company's prompt attention. Failure to act/fix the issues could result in the closure of one or more of the sites until the remedies are in place.
    • Ms. Bresch says, "Since Mylan acquired the Agila injectables business in December 2013 to create a leading global injectables platform, we have been taking extensive action to integrate the Agila business into Mylan's One Quality Standard and to ensure our leading position as a high quality, reliable source of injectables for the long term. As part of this ongoing process, we have a deep and unwavering commitment to quality everywhere we operate. We have been and will continue to work diligently to address all of the FDA's observations and have made important progress."
    | Tue, Aug. 18, 1:40 PM | 1 Comment
  • Fri, Aug. 14, 9:08 AM
    • Saying the deal faces too many hurdles, influential shareholder vote advisor Institutional Shareholder Services (ISS) recommends that Mylan (NASDAQ:MYL) stockholders vote against the company's bid for Perrigo (NYSE:PRGO).
    • In a report issued today, ISS cites "unreasonable uncertainties" that PRGO shareholders will reject the offer (not surprising), not least because the current value of Mylan's stock-and-cash bid is now worth only $200 compared to $232 when it was announced.
    • Mylan shareholders are scheduled to vote on the deal on August 28.
    | Fri, Aug. 14, 9:08 AM | 2 Comments
  • Thu, Aug. 13, 2:08 PM
    • Perrigo (PRGO +3.3%) Chairman, President & CEO Joseph Papa has a low opinion of Mylan's (MYL -1.2%) lowering of the acceptance condition for its bid to "greater than 50%" of PRGO voting shares instead of the original "not less than 80%."
    • He says, "Mylan already proposed a dilutive deal that substantially undervalues Perrigo; today's announcement makes it even worse. This scare tactic is simply an attempt to coerce Perrigo shareholders into a value destructive deal. We don't believe Perrigo shareholders will tender into this transaction at any threshold and we are confident that there is no rational path to a full acquisition of Perrigo. This move is an obvious sign of desperation that would have profoundly negative effects for shareholders, debt holders, customers and employees of both Perrigo and Mylan. Under Irish law, this structure all but guarantees that the promised synergy realization will fail and it would create material credit and equity risk for both companies, none of which Mylan has detailed to its own shareholders or ours. This reckless action runs contrary to the best interests of both Perrigo and Mylan shareholders, taking a value destructive threshold and making it materially worse when Mylan fails to achieve the 80% threshold necessary for consolidation. This is yet another example of Mylan's leadership disregarding their fiduciary responsibilities to represent the best interests of shareholders."
    • The term "hostile takeover" seems particularly apt here.
    • Previously: Mylan lowers acceptance condition on Perrigo bid to greater than 50% (Aug. 13)
    | Thu, Aug. 13, 2:08 PM | 5 Comments
Company Description
Mylan NV together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.
Sector: Healthcare
Industry: Drugs - Generic
Country: United States